Remove category resource-topic pharmacy
article thumbnail

The New Health/Care is Patient-Led, Retail-Enabled – The GMDC Self-Care Summit

Health Populi

As you look at this “Wheel of SelfCare,” you see there are data gathered for each condition with stats on prevalence, insights into conditions, retail info on “basket size” of spending for products and the categories within those baskets, and geographic differences across patients living in different parts of the U.S.

Doctors 65
article thumbnail

CMS Issues a New “Advancing Interoperability and Improving Prior Authorization Processes” Proposed Rule

C&M Health Law

CMS proposes to require impacted payers (now including MAOs) to share certain prior authorization information through the Health Level 7® (HL7®) Fast Healthcare Interoperability Resources® (FHIR®) standard Patient Access API. Patient Access API. (i) iii) Payers would be required to report metrics about the use of Patient Access API.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

HIMSS22 Day 2 Roundup: Google Partners with MEDITECH, Microsoft’s Health Cloud Strategy Expansions

HIT Consultant

The acquisition includes the full Market Access Management Platform supporting pharma manufacturers, hub providers and pharmacies to improve patient access, speed to therapy and activation of affordability programs. EvinceMed is a provider in delivering end-to-end automation for specialty pharmaceutical transactions. Core standards.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2024

SQA

The products had been improperly regularized in ANVISA as cosmetics since they are indicated for injectable use, a form that is not authorized for this category of product. The purpose of the note is to clarify that products for invasive aesthetic treatments cannot be regularized in the category of cosmetics.

FDA 52
article thumbnail

The Health Consumer in 2024 – The Health Populi TrendCast

Jane Sarashon

Fidelity Investments recently explored this topic. Professor Galloway pointed out in his 2024 predictions the sheer scale that this new drug category could have on over 100 million Americans alone. adults had major, unexpected medical expenses in the past 12 months ranging from $1,000 to $1,999. Over one-half of U.S.